SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Sepracor-Looks very promising
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: dalroi who wrote (3144)6/1/1999 5:36:00 PM
From: BMcV  Read Replies (1) of 10280
 
Thanks for the info on UCB. SEPR's annual report says levocetirizine is pre-clinical; the PR says phase 3. So Peter's hypothesis that UCB has been working on this on their own seems plausible. Especially so for a company with one big product that they would try in every way to enhance.

Another example of SEPR's hidden value.

Perhaps this will spur Hoechst to pay for Allegra's European rights?
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News